{
  "prompt": {
    "prompt": "Original Transcript:\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\n Patient Details:\nName: [Fictional Name] Sarah Ahmed\n\n\nAge: 32\n\n\nBMI: 24.7 (weight 68 kg, height 1.66 m)\n\n\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\n\n\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\n\n\nBooking bloods and anomaly scans: Unremarkable\n\n\nHistory of Presenting Complaint:\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\nRelevant Obstetric History:\nPrevious pregnancy uncomplicated; term vaginal delivery.\n\n\nNo history of intrahepatic cholestasis in prior pregnancy.\n\n\nNo history of preterm labour or hypertensive disorders.\n\n\nRelevant Medical History:\nMild childhood asthma (not on regular treatment).\n\n\nNo known liver or gallbladder disease.\n\n\nMedications & Allergies:\nCurrently taking ferrous fumarate and pregnancy multivitamin.\n\n\nNo known drug allergies.\n\n\nSocial History:\nLives with husband and toddler son.\n\n\nNon-smoker; does not consume alcohol.\n\n\nWorks part-time as a dental nurse; currently on maternity leave.\n\n\nExamination Findings:\nGeneral: Alert and well, no jaundice noted.\n\n\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\n\n\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\n\n\nNo uterine tenderness or signs of labour.\n\n\nNo peripheral oedema; BP 118/74 mmHg.\n\n\nNotable Omissions (for testing purposes):\nNo documented baseline bile acid levels from booking bloods.\n\n\nNo record of fetal growth scan within the last 2 weeks.\n\n\nNo documentation of CTG to assess current fetal wellbeing.\n\n\nImpression:\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\nManagement Plan:\nInvestigations:\n\n\nSerum bile acids and liver function tests (LFTs) urgently.\n\n\nFasting bile acids if initial results are borderline.\n\n\nFull blood count and clotting screen (due to potential risk of coagulopathy).\n\n\nCTG to assess fetal wellbeing.\n\n\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\n\n\nMedical Management:\n\n\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\n\n\nConsider chlorphenamine for symptomatic relief of itching.\n\n\nOngoing Care and Delivery Planning:\n\n\nWeekly bile acids and LFTs.\n\n\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\n\n\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\n\n\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\n\n\nCounseling Provided:\n\n\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\n\n\nReassured about ongoing monitoring and early delivery plan.\n\n\nAdvised to monitor fetal movements closely and report any reduction.\n\n\nProvided written information and contact details for triage if symptoms worsen.\n\n\nDictated by: Dr. [Fictional Name] Patel\n Date: [Fictional Date]\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\n\n\n\nGuideline Analysis:\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptomatic relief, as it does not improve perinatal outcomes.  \n   Reason: The guideline explicitly states \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\" (bjog-2022-girling). UDCA should only be considered for itch relief, not as standard management.  \n\n2. **Different management plan** - Reduce frequency of CTG monitoring unless bile acids ≥100 µmol/L, as CTG does not predict or prevent stillbirth in ICP.  \n   Reason: Guideline states \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\" (bjog-2022-girling). Over-monitoring is not evidence-based.  \n\n3. **Improved patient advice** - Clarify that UDCA is for symptom relief only, not for reducing stillbirth risk.  \n   Reason: The guideline notes UDCA does not significantly impact perinatal outcomes (bjog-2022-girling). Patient should understand its limited role.  \n\n### Somewhat Important Recommendations  \n1. **Additional information needed** - Document baseline bile acid levels from booking bloods for comparison.  \n   Reason: Guideline recommends baseline measurements in subsequent pregnancies (bjog-2022-girling). Though this is a first ICP episode, baseline data helps track progression.  \n\n2. **Different management plan** - Consider discontinuing growth scans unless bile acids ≥100 µmol/L or other risk factors emerge.  \n   Reason: Guideline states ultrasound does not predict stillbirth (bjog-2022-girling). Routine scans may not be cost-effective.  \n\n3. **Improved patient advice** - Discuss increased risk of pre-eclampsia/GDM and need for monitoring.  \n   Reason: Guideline notes higher chance of these conditions in ICP (bjog-2022-girling). Proactive counseling is warranted.  \n\n### Less Important Recommendations  \n1. **Additional information needed** - Consider hepatitis C testing only if itch is severe/atypical.  \n   Reason: Guideline no longer recommends routine hepatitis C testing (bjog-2022-girling). Only needed in select cases.  \n\n2. **Improved patient advice** - Provide ICP Support/RCOG resources for patient education.  \n   Reason: Guideline lists these as useful links (bjog-2022-girling). Enhances patient understanding.  \n\n### Unimportant Recommendations  \n1. **Different management plan** - Vitamin K supplementation could be mentioned but is not routinely needed.  \n   Reason: Guideline only recommends it for steatorrhoea/coagulopathy (bjog-2022-girling). No evidence of either here.  \n\n2. **Additional information needed** - Postnatal follow-up timing could be specified (4+ weeks).  \n   Reason: Guideline recommends confirming resolution postnatally (bjog-2022-girling). Minor documentation improvement.  \n\nKey areas to address are reducing non-evidence-based interventions (UDCA, excessive monitoring) and improving patient counseling about risks/limitations of treatments. The note generally aligns well but could better reflect guideline nuances.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 53 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nPlease extract actionable suggestions from this analysis and format them as specified.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"brief explanation of why this change is suggested\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis\n- Make suggestions specific and actionable\n- Ensure original text selections are precise and findable in the transcript\n- Keep context explanations concise but informative\n- Prioritize suggestions based on clinical importance\n- If no specific suggestions can be made, return {\"suggestions\": []}",
    "transcript_length": 3421,
    "analysis_length": 3383,
    "guideline_id": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf",
    "guideline_title": "Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management"
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid 500 mg BID for symptomatic relief of itching if needed, while awaiting results.\",\n      \"context\": \"UDCA should not be routinely offered for adverse perinatal outcomes, only for symptom relief\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling - Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Consider CTG monitoring only if bile acids ≥100 µmol/L, as routine CTG does not predict stillbirth.\",\n      \"context\": \"CTG monitoring should be reduced unless bile acids are ≥100 µmol/L\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling - Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\",\n      \"suggestedText\": \"Discussed nature of obstetric cholestasis, increased risk of stillbirth in twin pregnancies, and clarified that UDCA is for symptom relief only, not for reducing stillbirth risk.\",\n      \"context\": \"Patient should understand UDCA's limited role in symptom management\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling - UDCA does not significantly impact perinatal outcomes\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"No documented baseline bile acid levels from booking bloods.\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods for comparison if available.\",\n      \"context\": \"Baseline measurements help track progression in subsequent pregnancies\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"bjog-2022-girling - Baseline measurements recommended in subsequent pregnancies\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Counseling Provided section\",\n      \"suggestedText\": \"Add discussion about increased risk of pre-eclampsia/GDM and need for monitoring to Counseling Provided section.\",\n      \"context\": \"Higher chance of these conditions in ICP warrants proactive counseling\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"bjog-2022-girling - Higher chance of pre-eclampsia/GDM in ICP\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Counseling Provided section\",\n      \"suggestedText\": \"Add provision of ICP Support/RCOG resources to Counseling Provided section.\",\n      \"context\": \"Enhances patient understanding through additional resources\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"bjog-2022-girling - Lists ICP Support/RCOG as useful links\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-06-10T18-44-48",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\\n Patient Details:\\nName: [Fictional Name] Sarah Ahmed\\n\\n\\nAge: 32\\n\\n\\nBMI: 24.7 (weight 68 kg, height 1.66 m)\\n\\n\\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\\n\\n\\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\\n\\n\\nBooking bloods and anomaly scans: Unremarkable\\n\\n\\nHistory of Presenting Complaint:\\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\\nRelevant Obstetric History:\\nPrevious pregnancy uncomplicated; term vaginal delivery.\\n\\n\\nNo history of intrahepatic cholestasis in prior pregnancy.\\n\\n\\nNo history of preterm labour or hypertensive disorders.\\n\\n\\nRelevant Medical History:\\nMild childhood asthma (not on regular treatment).\\n\\n\\nNo known liver or gallbladder disease.\\n\\n\\nMedications & Allergies:\\nCurrently taking ferrous fumarate and pregnancy multivitamin.\\n\\n\\nNo known drug allergies.\\n\\n\\nSocial History:\\nLives with husband and toddler son.\\n\\n\\nNon-smoker; does not consume alcohol.\\n\\n\\nWorks part-time as a dental nurse; currently on maternity leave.\\n\\n\\nExamination Findings:\\nGeneral: Alert and well, no jaundice noted.\\n\\n\\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\\n\\n\\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\\n\\n\\nNo uterine tenderness or signs of labour.\\n\\n\\nNo peripheral oedema; BP 118/74 mmHg.\\n\\n\\nNotable Omissions (for testing purposes):\\nNo documented baseline bile acid levels from booking bloods.\\n\\n\\nNo record of fetal growth scan within the last 2 weeks.\\n\\n\\nNo documentation of CTG to assess current fetal wellbeing.\\n\\n\\nImpression:\\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\\nManagement Plan:\\nInvestigations:\\n\\n\\nSerum bile acids and liver function tests (LFTs) urgently.\\n\\n\\nFasting bile acids if initial results are borderline.\\n\\n\\nFull blood count and clotting screen (due to potential risk of coagulopathy).\\n\\n\\nCTG to assess fetal wellbeing.\\n\\n\\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\\n\\n\\nMedical Management:\\n\\n\\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\\n\\n\\nConsider chlorphenamine for symptomatic relief of itching.\\n\\n\\nOngoing Care and Delivery Planning:\\n\\n\\nWeekly bile acids and LFTs.\\n\\n\\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\\n\\n\\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\\n\\n\\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\\n\\n\\nCounseling Provided:\\n\\n\\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\\n\\n\\nReassured about ongoing monitoring and early delivery plan.\\n\\n\\nAdvised to monitor fetal movements closely and report any reduction.\\n\\n\\nProvided written information and contact details for triage if symptoms worsen.\\n\\n\\nDictated by: Dr. [Fictional Name] Patel\\n Date: [Fictional Date]\\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\\n\\n\\n\\nGuideline Analysis:\\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptomatic relief, as it does not improve perinatal outcomes.  \\n   Reason: The guideline explicitly states \\\"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\\\" (bjog-2022-girling). UDCA should only be considered for itch relief, not as standard management.  \\n\\n2. **Different management plan** - Reduce frequency of CTG monitoring unless bile acids ≥100 µmol/L, as CTG does not predict or prevent stillbirth in ICP.  \\n   Reason: Guideline states \\\"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\\\" (bjog-2022-girling). Over-monitoring is not evidence-based.  \\n\\n3. **Improved patient advice** - Clarify that UDCA is for symptom relief only, not for reducing stillbirth risk.  \\n   Reason: The guideline notes UDCA does not significantly impact perinatal outcomes (bjog-2022-girling). Patient should understand its limited role.  \\n\\n### Somewhat Important Recommendations  \\n1. **Additional information needed** - Document baseline bile acid levels from booking bloods for comparison.  \\n   Reason: Guideline recommends baseline measurements in subsequent pregnancies (bjog-2022-girling). Though this is a first ICP episode, baseline data helps track progression.  \\n\\n2. **Different management plan** - Consider discontinuing growth scans unless bile acids ≥100 µmol/L or other risk factors emerge.  \\n   Reason: Guideline states ultrasound does not predict stillbirth (bjog-2022-girling). Routine scans may not be cost-effective.  \\n\\n3. **Improved patient advice** - Discuss increased risk of pre-eclampsia/GDM and need for monitoring.  \\n   Reason: Guideline notes higher chance of these conditions in ICP (bjog-2022-girling). Proactive counseling is warranted.  \\n\\n### Less Important Recommendations  \\n1. **Additional information needed** - Consider hepatitis C testing only if itch is severe/atypical.  \\n   Reason: Guideline no longer recommends routine hepatitis C testing (bjog-2022-girling). Only needed in select cases.  \\n\\n2. **Improved patient advice** - Provide ICP Support/RCOG resources for patient education.  \\n   Reason: Guideline lists these as useful links (bjog-2022-girling). Enhances patient understanding.  \\n\\n### Unimportant Recommendations  \\n1. **Different management plan** - Vitamin K supplementation could be mentioned but is not routinely needed.  \\n   Reason: Guideline only recommends it for steatorrhoea/coagulopathy (bjog-2022-girling). No evidence of either here.  \\n\\n2. **Additional information needed** - Postnatal follow-up timing could be specified (4+ weeks).  \\n   Reason: Guideline recommends confirming resolution postnatally (bjog-2022-girling). Minor documentation improvement.  \\n\\nKey areas to address are reducing non-evidence-based interventions (UDCA, excessive monitoring) and improving patient counseling about risks/limitations of treatments. The note generally aligns well but could better reflect guideline nuances.\\n\\n\\n## Summary\\n\\nAnalyzed against the most relevant guideline successfully.\\n\\n*Note: Found 53 relevant guidelines total, analyzed against the most relevant one.*\\n\\n\\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nPlease extract actionable suggestions from this analysis and format them as specified.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"brief explanation of why this change is suggested\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis\\n- Make suggestions specific and actionable\\n- Ensure original text selections are precise and findable in the transcript\\n- Keep context explanations concise but informative\\n- Prioritize suggestions based on clinical importance\\n- If no specific suggestions can be made, return {\\\"suggestions\\\": []}\",\n  \"transcript_length\": 3421,\n  \"analysis_length\": 3383,\n  \"guideline_id\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\",\n  \"guideline_title\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid 500 mg BID for symptomatic relief of itching if needed, while awaiting results.\",\n      \"context\": \"UDCA should not be routinely offered for adverse perinatal outcomes, only for symptom relief\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling - Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Consider CTG monitoring only if bile acids ≥100 µmol/L, as routine CTG does not predict stillbirth.\",\n      \"context\": \"CTG monitoring should be reduced unless bile acids are ≥100 µmol/L\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling - Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\",\n      \"suggestedText\": \"Discussed nature of obstetric cholestasis, increased risk of stillbirth in twin pregnancies, and clarified that UDCA is for symptom relief only, not for reducing stillbirth risk.\",\n      \"context\": \"Patient should understand UDCA's limited role in symptom management\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"bjog-2022-girling - UDCA does not significantly impact perinatal outcomes\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"No documented baseline bile acid levels from booking bloods.\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods for comparison if available.\",\n      \"context\": \"Baseline measurements help track progression in subsequent pregnancies\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"bjog-2022-girling - Baseline measurements recommended in subsequent pregnancies\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Counseling Provided section\",\n      \"suggestedText\": \"Add discussion about increased risk of pre-eclampsia/GDM and need for monitoring to Counseling Provided section.\",\n      \"context\": \"Higher chance of these conditions in ICP warrants proactive counseling\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"bjog-2022-girling - Higher chance of pre-eclampsia/GDM in ICP\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Counseling Provided section\",\n      \"suggestedText\": \"Add provision of ICP Support/RCOG resources to Counseling Provided section.\",\n      \"context\": \"Enhances patient understanding through additional resources\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"bjog-2022-girling - Lists ICP Support/RCOG as useful links\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 1799\nCompletion tokens: 722\nTotal tokens: 2521\nEstimated cost: $0.001260",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 1799,
    "completion_tokens": 722,
    "total_tokens": 2521,
    "estimated_cost_usd": 0.0012605
  }
}